Licensing and prescribing biosimilars in Australia

Author(s): Professor David A Power, MD, PhD, FRCP, FRACP

Abstract: Some years ago, Australian regulatory authorities decided to follow the path laid down by the European Medicines Agency in adopting a process for approval of biosimilars. This has been a largely successful process, resulting in the licensing of biosimilars for many peptides, especially epoetin and granulocyte colony-stimulating factor (G-CSF). Aside from the availability of […]

Read more →